5-MeO-DPAC, also known as 5-methoxy-3-(dipropylamino)chroman, is a potent and highly selective serotonin 5-HT<sub>1A</sub> receptor full agonist related to 8-OH-DPAT. It is a derivative of 3-aminochroman, in which in the 5th position of the benzene ring there is a methoxy group, and in the 3rd position of dipropylamine.
The drug shows no affinity for other serotonin receptors or for the dopamine D<sub>2</sub> receptor. It acts at very low concentrations, albeit with lower potency than 8-OH-DPAT, and unlike 8-OH-DPAT, does not bind to presynaptic serotonin 5-HT<sub>1A</sub> receptors in the striatum.
The mechanism of action of 5-MeO-DPAC is to reduce the synthesis and turnover of serotonin in the brain through selective activation of serotonin 5-HT<sub>1A</sub> autoreceptors, which is mediated through a negative feedback system without a direct effect on striatal binding sites.
5-MeO-DPAC was first described in the scientific literature by 1987.